Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DW1807-R2
- Development stage
- Unknown
- Lead developer
- Daewon Pharm
- Administration
- Oral, Intranasal
01
Overview
DW1807-R2 is an experimental formulation being evaluated in clinical trials as a potential treatment for perennial allergic rhinitis accompanied by comorbid asthma. It is being compared directly against DW1807 in a randomized Phase 3 clinical trial, with the primary objective to compare their effects on the reflective total nasal symptom score (rTNSS) after 4 weeks of treatment in patients with both perennial allergic rhinitis and asthma. Its precise mechanism of action, composition, and molecular modality have not been publicly detailed in available sources, but it is clearly an investigational pharmaceutical candidate under development for allergic and respiratory conditions[1][2][3][5].
Beyond the preview
Go deeper on DW1807-R2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DW1807-R2.